🇨🇭·Apr 21Industry
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Publisher
R
Roche Newsroom
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- April 21, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences·21h ago
Company - Sellas Life Sciences
Hyman, Phelps & McNamara (FDA Law)·22h ago
WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage
Sumitomo Pharma·1d ago
Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia
Menicon·1d ago